Cover Image
市場調查報告書

左心室功能障礙 : 開發平台分析

Left Ventricular Dysfunction - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 246004
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
左心室功能障礙 : 開發平台分析 Left Ventricular Dysfunction - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 62 Pages
簡介

左心室功能障礙(LVD)或是接著引起的鬱血性心衰竭(CHF)常是造成各種心臟疾病的最終要因。冠狀動脈的堵塞及缺血性心臟疾病佔心臟衰竭原因的大半,同時也常與急性/陳舊性心肌梗塞有關。其他原因還有心肌病和高血壓,以及其他各種要因(瓣膜症,心肌炎等)。這個疾病一般與心臟衰竭和心肌梗塞,其他心血管併發症相關。可以射血分數過低,左心室壁可動性低診斷出。

本報告提供全球各國治療左心室功能障礙用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

左心室功能障礙概要

治療藥的開發

  • 左心室功能障礙開發中產品:概要
  • 左心室功能障礙開發中產品:比較分析

各企業開發中的左心室功能障礙治療藥

大學/研究機關研究中的左心室功能障礙治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

左心室功能障礙治療藥:開發中的產品一覽(各企業)

左心室功能障礙治療藥:研究中的產品一覽(大學/研究機關別)

左心室功能障礙開發治療藥的企業

  • Acorda Therapeutics, Inc.
  • Amgen Inc.
  • Bayer AG
  • Innopharmax Inc.
  • RedHill Biopharma Ltd.
  • TiGenix NV

左心室功能障礙:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • BAY-1142524
  • CAP-1001
  • CAP-1002
  • carvedilol CR
  • carvedilol CR
  • cimaglermin alfa
  • CTX-101
  • omecamtiv mecarbil

左心室功能障礙治療藥:最新開發平台趨勢

左心室功能障礙治療藥:暫停開發的產品

左心室功能障礙治療藥:中止開發的產品

左心室功能障礙相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8939IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Left Ventricular Dysfunction - Pipeline Review, H1 2017, provides an overview of the Left Ventricular Dysfunction (Cardiovascular) pipeline landscape.

Left ventricular dysfunction is the most common cause of congestive heart failure. Symptoms include fluid retention, dizziness, fatigue, weakness, irregular heart beat and congested lungs. Risk factors include high blood pressure, diabetes, sleep apnea, alcoholism and coronary artery disease.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Left Ventricular Dysfunction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Left Ventricular Dysfunction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 7 and 2 respectively.

Left Ventricular Dysfunction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Left Ventricular Dysfunction (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Left Ventricular Dysfunction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Left Ventricular Dysfunction (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Left Ventricular Dysfunction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Left Ventricular Dysfunction - Overview
  • Left Ventricular Dysfunction - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Left Ventricular Dysfunction - Companies Involved in Therapeutics Development
  • Amgen Inc
  • Bayer AG
  • Capricor Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Innopharmax Inc
  • Les Laboratoires Servier SAS
  • Quantum Genomics SA
  • RedHill Biopharma Ltd
  • TiGenix NV
  • Left Ventricular Dysfunction - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Left Ventricular Dysfunction - Drug Profiles
  • BAY-1142524 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CAP-1001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CAP-1002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • carvedilol CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • carvedilol phosphate CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CTX-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NP-202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • omecamtiv mecarbil MR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pirfenidone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • QGC-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • S-38844 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Left Ventricular Dysfunction - Dormant Projects
  • Left Ventricular Dysfunction - Discontinued Products
  • Left Ventricular Dysfunction - Product Development Milestones
  • Featured News & Press Releases
  • Aug 27, 2013: Amgen to Highlight New Data at Upcoming ESC Congress 2013
  • Jun 18, 2013: Cytokinetics Announces Presentation Of Results From Phase IIb Clinical Trial Of Omecamtiv Mecarbil At ESC Congress 2013
  • Feb 19, 2013: RedHill Biopharma Announces Notice Of Allowance From US Patent And Trademark Office For Cardio Drug RHB-101
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Left Ventricular Dysfunction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Left Ventricular Dysfunction - Pipeline by Amgen Inc, H1 2017
  • Left Ventricular Dysfunction - Pipeline by Bayer AG, H1 2017
  • Left Ventricular Dysfunction - Pipeline by Capricor Therapeutics Inc, H1 2017
  • Left Ventricular Dysfunction - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Left Ventricular Dysfunction - Pipeline by Innopharmax Inc, H1 2017
  • Left Ventricular Dysfunction - Pipeline by Les Laboratoires Servier SAS, H1 2017
  • Left Ventricular Dysfunction - Pipeline by Quantum Genomics SA, H1 2017
  • Left Ventricular Dysfunction - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Left Ventricular Dysfunction - Pipeline by TiGenix NV, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Left Ventricular Dysfunction - Dormant Projects, H1 2017
  • Left Ventricular Dysfunction - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Left Ventricular Dysfunction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top